MSI colon cancer: is adjuvant therapy warranted?

Aziz Zaanan; Olivier Dubreuil; Isabelle Trouilloud; Pierre Laurent-Puig; Julien Taieb

doi:10.1684/hpg.2012.0714



Printable version
MSI colon cancer: is adjuvant therapy warranted?
Hépato-Gastro. Volume 19, Number 4, 242-7, Avril 2012, Mini-revue
Résumé Texte intégral
Author(s) : Aziz Zaanan, Olivier Dubreuil, Isabelle Trouilloud, Pierre Laurent-Puig, Julien Taieb
Summary : Microsatellite instability (MSI) phenotype occurs in approximately 15% of colorectal cancer (CRC) patients and may be sporadic or hereditary. Several studies have shown that patients with MSI CRC have a more favourable prognosis than those who have microsatellite stable CRC. Recent clinical data indicate that patients with hereditary MSI tumor treated with 5-fluorouracil (5-FU) as adjuvant chemotherapy may have a survival advantage, in contrast to sporadic forms that would not benefit. However, the benefit of oxaliplatin-based adjuvant regimens regarding MSI phenotype remains poorly investigated. Some preliminary data from retrospective studies suggest that addition of oxaliplatin to 5-FU could provide a survival advantage for patients with stage III MSI tumor. Nevertheless, these results should be confirmed by ongoing analysis of tumor samples from previously published randomized trials comparing 5-FU to FOLFOX (NSABP-C07 and MOSAIC studies).
Keywords : Colon cancer, microsatellite instability, prognosis, adjuvant chemotherapy